Home Investment SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial – Stock Soars with Triple Digit Gains

SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial – Stock Soars with Triple Digit Gains

by Deidre Salcido
0 comments
111726 1.jpg


SELLAS is trading at 20.20, up 170.42% on volume of over 72 million shares, after positive topline Phase 3 results for its cancer vaccine in acute myeloid leukemia.

Investorideas.com (www.investorideas.com) a trusted platform for investing ideas, including biotech and medical tech stocks, issues a news and trading alert for SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications.

The stock makes the Nasdaq top gainer list today following news. SELLAS is trading at 20.20 +12.73 (+170.42%) on volume of over 72 Million shares as of this report. The stock has a morning high of $24.89- making a 52 week high.

SELLAS Life Sciences today announced positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.


Advertisement

The REGAL trial met its primary endpoint of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with investigator’s choice of best available treatment (BAT). In the trial, GPS showed a 41% reduction in the risk of death (hazard ratio of 0.59) and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (grade 1/2), most commonly consisting of local injection site reactions. Both treatment arms were well balanced for prognostic stratification factors. Patients who proceeded to hematopoietic stem cell transplantation were limited in number and equally distributed between the study arm and control arm.

“We are deeply grateful to the patients and their families, investigators, clinical teams, and everyone who contributed to REGAL over the course of this study. Their commitment has helped make this important milestone possible,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.

Dr. Stergiou continued, “REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission. The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for SELLAS and provides Phase 3 validation of our WT1-targeted immunotherapeutic technology. We also believe GPS has the potential to become an important paradigm-shifting option for this high-risk population that desperately needs effective therapies. Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible.”

The topline primary endpoint data analysis was conducted following the pre-specified occurrence of 80 events (deaths) in accordance with the trial’s pre-specified statistical analysis plan (SAP). Based on these results, SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated filing strategy and advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027. In accordance with standard registrational trial reporting practices, comprehensive statistical evaluation of all secondary endpoints and additional pre-specified analyses per the SAP and study protocol is underway and will be presented in detail at an upcoming major medical conference and submitted for publication in a peer-reviewed journal.

“Patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and have a significant need for new treatment approaches. The landmark data from the Phase 3 REGAL trial demonstrate a statistically significant and clinically meaningful overall survival advantage for the GPS immunotherapeutic cancer vaccine in this underserved population. By training the immune system to target residual leukemia cells, GPS addresses a critical unmet need and has the potential to redefine the treatment paradigm in AML maintenance therapy. We look forward to sharing the detailed results from REGAL with the medical community at a future scientific meeting,” commented the members of the REGAL Study Steering Committee.

The REGAL Study Steering Committee comprises Hagop M. Kantarjian, MD, Professor, Department of Leukemia and Samsung Distinguished Leukemia Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center, Chair of the REGAL Study Steering Committee and global Principal Investigator of the REGAL trial; Javier Pinilla-Ibarz, MD, PhD, Director of Immunotherapy and Head of the Lymphoma Section, Department of Malignant Hematology at Moffitt Cancer Center; and M. Yair Levy, MD, Director of Hematologic Malignancies Research at Texas Oncology-Baylor Charles A. Sammons Cancer Center.

Research biotech stocks at the free stock directory at Investorideas.com

Learn more about becoming a featured annual biotech stock or be featured in a trading alert

https://www.investorideas.com/bis/stock_list.asp

About Investorideas.com & Contact Info

https://www.investorideas.com/about/

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as AI, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, AI-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

Why partner with Investor Ideas?

Discover our powerful news, PR, social media, and podcast solutions at Investorideas.com

https://www.investorideas.com/investors/services.asp

Digital advertising and guest posts

https://www.investorideas.com/advertise/

Follow us

X: @investorideas   @stocknewsbites

Facebook: https://www.facebook.com/Investorideas

YouTube: https://www.youtube.com/c/Investorideas

Free stock news alerts

https://www.investorideas.com/resources/newsletter.asp

Free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

Contact

Call 800 665 0411


Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published/created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer and disclosure info: https://www.investorideas.com/about/disclaimer.asp

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/about/private_policy.asp



You may also like

Leave a Comment

About Us

Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.

© 2025 AI Investor Picks – All Rights Reserved

AI Investor Picks